acute coronary syndrome
Cardiovascular · 2008–2024
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| prasugrel Treatment of acute coronary syndrome (myocardial infarction or unstable angina) managed by percutaneous coronary intervention (PCI), in combination with… | Jul 2024 | Recommended with restriction | none received |
| prasugrel Acute coronary syndrome (myocardial infarction or unstable angina) managed by percutaneous coronary intervention (PCI), in combination with aspirin. | Mar 2024 | Not recommended | input received National Aboriginal Community Controlled Health Organisation |
| ticagrelor Treatment of acute coronary syndrome (ACS) including unstable angina, non-ST elevation myocardial infarction, or ST elevation myocardial infarction, in… | Mar 2023 | Not recommended | none received |
| ticagrelor Treatment of acute coronary syndromes (myocardial infarction or unstable angina) in combination with aspirin. | Jul 2011 | Recommended with restriction | no section in document |
| prasugrel hydrochloride Treatment of acute coronary syndromes (myocardial infarction or unstable angina) in combination with aspirin in patients who are to undergo percutaneous… | Jul 2009 | Recommended with restriction | no section in document |
| clopidogrel hydrogen sulfate Treatment of acute coronary syndromes (myocardial infarction or unstable angina) in combination with aspirin to prevent early and long-term atherothrombotic… | Mar 2008 | Recommended with restriction | no section in document |
Who spoke
National Aboriginal Community Controlled Health Organisation
What the PBS pays
$27M in government benefit over 2024–25, across 221,281 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| ticagrelor | $27.1M |
| prasugrel | $0M |
Appraised elsewhere
NICE, in England and Wales, has appraised 4 technologies for this condition, recommending 3 . A different committee, a different population and a different price: this is what has been looked at there, not a verdict on what happened here.
| Technology | Appraisal | Outcome | Date |
|---|---|---|---|
| rivaroxabanRivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome | TA335 | recommended | 2015-03 |
| prasugrelPrasugrel with percutaneous coronary intervention for treating acute coronary syndromes | TA317 | recommended | 2014-07 |
| ticagrelorTicagrelor for the treatment of acute coronary syndromes | TA236 | recommended | 2011-10 |
| guidance on the use of glycoprotein iib iiia inhibitorsGuidance on the use of glycoprotein IIb/IIIa inhibitors in the treatment of acute coronary syndromes | TA47 | unknown | 2002-09 |
Registered, not subsidised
Medicines on the ARTG for this condition with no PBAC record at all. Registration and subsidy are separate decisions: a medicine can be legally available in Australia and never have been put to the committee.
| Medicine | On the ARTG since | Registrations |
|---|---|---|
| clopidogrelAPX-CLOPIDOGREL clopidogrel (as besilate) 75 mg tablet blister pack | 2001 | 34 |
| bivalirudinAPO-Bivalirudin bivalirudin (as trifluoroacetate) 250mg powder for inj | 2015 | 10 |
| aspirin + clopidogrelAPX-CLOPIDOGREL/ASPIRIN 75/100 clopidogrel (as hydrogen sulfate)/aspir | 2009 | 5 |
| eptifibatideEPTIFIBATIDE MEDICIANZ eptifibatide (as acetate) 20 mg/10 mL solution | 2025 | 4 |
The ARTG export holds current registrations only, so the year is the earliest entry still on the register rather than a first-registration date. The condition here comes from the registered label, which is usually broader than the population a sponsor asks to have subsidised.
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 3 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.